Signature Blue_CRC was generated based on 3 training colorectal  cancer cohorts and validated in another 20 independent cancer cohorts (n = 6,067).  Cox regression analysis showed that this signature well predicted recurrence survival in almost all of the cohorts when either all stages of cancers (Fig.1) or stage 2&3 cancers (Fig.2) were tested.   The prediction power of this signature in stage 2&3 cancers was also confirmed in Kaplan-Meier analysis (Fig.3).   


Fig. 1  Associations of Blue_CRC score with survival in cancers at all stages.  The hazard ratio (HR) was shown in forest plot.  Twenty three independent  cancer cohorts (n =  6,067) were analyzed.  In some of the cohorts, tumors are all or mainly at stage 2 & 3.     The overall effect was calculated through a random-effects (RE) model.  



Fig. 2  Associations of Blue_CRC score with survival in stage 2&3 cancers.   Only stage 2&3 cancers were analyzed here. The hazard ratio (HR) was shown in forest plot.



Fig. 3  Kaplan-Meier analysis of the association of BlueCRC score with recurrence risk in stage 2&3 cancers. Only stage 2&3 cancers were analyzed here.   Each Kaplan-Meier plot represents an analysis result for one cohort. Â